股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 維昇藥業 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02561 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.0001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 500,000,000 | USD | | 0.0001 | USD | | 50,000 | 本月底法定 ...

Group 1 - The stock of Vison Pharmaceutical-B (02561.HK) has increased by over 4%, currently up 4.68%, trading at 39.8 HKD [2]

Core Viewpoint - The recent prescription of Palopegteriparatide at a hospital in Hainan marks a significant milestone for the company in the endocrine innovation field, with the drug being the first and only parathyroid hormone replacement therapy globally [1][2]. Group 1: Company Developments - The stock of Viesheng Pharmaceutical (02561) rose by 4.68%, reaching HKD 39.8 [1]. - The CEO of Viesheng Pharmaceutical highlighted the importance of the first prescription of Palopegteriparatide as a step towards innovation in the endocrine sector [1]. - The company is committed to accelerating the domestic approval process for Palopegteriparatide and continuing its focus on innovative endocrine therapies [1]. Group 2: Product Pipeline - The company is advancing its long-acting growth hormone, Long-acting Growth Hormone, which is expected to be approved for domestic use in the second half of 2025, potentially becoming the third long-acting growth hormone in China [2]. - Viesheng Pharmaceutical has two unique products, namely Navepeptide and Palopegteriparatide, with the latter expected to submit a market application by the end of 2025 [2]. - Collaborations with WuXi Biologics and Anke Bio are in place to enhance local production and commercialize products, indicating a promising market outlook [2].

Group 1 - The core point of the news is that Viesheng Pharmaceutical-B (02561) has seen a stock increase of over 4%, attributed to the first prescription of Palopegteriparatide at a hospital in Hainan, marking a significant milestone for the company in the endocrine field [1] - Palopegteriparatide is the first and only parathyroid hormone replacement therapy approved in major markets in Europe and the US, indicating its potential to address traditional treatment challenges for patients [1] - The CEO of Viesheng Pharmaceutical emphasized the importance of this prescription as a step towards innovation in endocrine therapies and the company's commitment to accelerating the drug's approval process in China [1] Group 2 - The company is advancing its long-acting growth hormone, Longpei Growth Hormone, which is expected to be approved for domestic market launch in the second half of 2025, potentially becoming the third long-acting growth hormone in China [2] - Viesheng Pharmaceutical has two unique products, including Palopegteriparatide, which is anticipated to submit a market application by the end of 2025 [2] - Collaborations with WuXi Biologics and Anke Bio have been established to enhance local production and commercialization efforts, indicating a promising market outlook for the company's products [2]

Core Viewpoint - The appointment of Mr. Lu Ying as the Chief Financial Officer of Weisheng Pharmaceutical-B (02561.HK) is a strategic move aimed at enhancing the company's financial management and investor relations capabilities [3]. Group 1: Appointment Details - Weisheng Pharmaceutical-B announced the appointment of Mr. Lu Ying as CFO effective from October 13, 2025 [3]. - Mr. Lu Ying, aged 41, has over 19 years of financial management experience [3]. Group 2: Previous Experience - Prior to joining Weisheng Pharmaceutical, Mr. Lu served as CFO at Weimou Biotechnology (Zhejiang) Co., Ltd. from August 2021 to October 2025, focusing on corporate financing and investor relations [3]. - He held the position of Financial Director at Allergan Information Consulting (Shanghai) Co., Ltd. from August 2020 to August 2021, overseeing financial management and strategic planning [3]. - Mr. Lu worked at Bayer A.G. in various financial management roles from September 2010 to August 2020, with his last position being CFO of Bayer Healthcare, responsible for overall financial management in Hong Kong [3]. - Earlier in his career, he was a Senior Accountant at PwC from August 2006 to February 2010 [3]. Group 3: Educational Background - Mr. Lu obtained a Bachelor's degree in Economic and Trade English from Shanghai University of Finance and Economics in June 2006 [3].

Core Points - The company announced the appointment of Lu Ying as the Chief Financial Officer, effective from October 13, 2025 [1] Group 1 - Lu Ying has been appointed as the Chief Financial Officer of the company [1]

Core Viewpoint - Vison Pharmaceutical-B (02561.HK) announced the appointment of Lu Ying as the Chief Financial Officer, effective from October 13, 2025 [1] Company Summary - Lu Ying has been appointed as the Chief Financial Officer of Vison Pharmaceutical-B [1]

Core Viewpoint - Vison Pharmaceutical-B (02561) announced the appointment of Lu Ying as the Chief Financial Officer, effective from October 13, 2025 [1] Group 1 - Lu Ying has been appointed as the Chief Financial Officer of Vison Pharmaceutical-B [1]

陸先生於2006年6月自上海財經大學取得經貿英語文學學士學位。 董事會謹此熱烈歡迎陸先生履新。 承董事會命 維昇藥業 執行董事兼首席執行官 盧安邦先生 VISEN Pharmaceuticals 維昇藥業 （於開曼群島註冊成立的有限公司） （股份代號：2561） 委任首席財務官 維昇藥業（「本公司」及其附屬公司「本集團」）董事（「董事」）會（「董事會」）欣然宣 布陸楹先生（「陸先生」）已獲委任為本公司首席財務官，自2025年10月13日起生 效。 陸楹先生，41歲，擁有逾19年的財務管理經驗。加入本集團之前，陸先生自2021 年8月至2025年10月擔任維眸生物科技（浙江）有限公司首席財務官（該公司是一 家開發眼部疾病創新療法的臨床階段製藥公司），負責統籌管理企業融資、投資 者關係及財務管理。在此之前，彼自2020年8月至2021年8月擔任艾爾建信息諮詢 （上海）有限公司財務總監，負責財務管理、戰略規劃、內部控制及合併後整合。 陸先生自2010年9月至2020年8月在Bayer A.G.集團內擔任多個財務管理職位，其 在此擔任的最後職位為拜耳醫療保健有限公司首席財務官，主要負責拜耳在香港 醫療保健業務的整體財 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 維昇藥業 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02561 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | | 本月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | | 50,000 | 本月底法定/ ...